Since it isn't Big Pharma Profit, it's not viable.
Except it IS, just like HCQ and Ivermectin.
Researchers say their clinical trial using a cheap asthma inhaler to prevent COVID-19 patients developing severe symptoms has produced “incredible” results....
...“When we first began the trial back in March , we were hoping for 50 per cent reduction [in risk of developing serious symptoms], which itself would have been very high,” he said.
“We got 90 per cent, which even with only a few hundred people is off the charts.
“And it’s not just the overall result - their temperatures are less, they get less fever, and they recover faster.”...
The big hospital systems will not likely allow their doctors to prescribe this, just as they would not allow HCQ/Zpak nor Ivermectin. Kinda tells you a lot, doesn't it?
Post a Comment